Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros

Tipo de documento
Intervalo de ano de publicação
3.
Eur J Intern Med ; 26(4): e1-2, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25214007

RESUMO

A 40-year-old man presented with an eight day history of left-side pleuritic chest pain and dyspnea. Chest examination revealed decreased air entry at the left lung. Chest X-ray examination revealed a large pneumothorax and a chest tube was successfully placed. Two hours after the procedure, auscultation revealed crackles over the left lung and oxygen saturation was 88% on room air. Chest radiography was repeated and showed a fully expanded left lung with alveolar-interstitial infiltrates.


Assuntos
Pneumotórax/complicações , Pneumotórax/diagnóstico por imagem , Insuficiência Respiratória/diagnóstico , Adulto , Dor no Peito , Dispneia , Humanos , Pulmão/diagnóstico por imagem , Masculino , Radiografia Torácica
4.
Congest Heart Fail ; 15(5): 252-3, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19751430

RESUMO

Unilateral pulmonary edema is an uncommon clinical situation that may be difficult to distinguish from other conditions that cause lung infiltrates. Most cases occur in the right lung, and there are no reports about cardiogenic unilateral pulmonary edema as a complication of an endoscopic procedure of gastrointestinal tract. The authors describe a case of a 79-year-old woman with acute cardiac heart failure that developed soon after a diagnostic upper and lower digestive endoscopy. Continuous positive airway pressure, intravenous nitroglycerin, and furosemide treatment resulted in rapid improvement of symptoms and the progressive resolution of left-sided infiltrates on chest radiography. This case is of particular importance because of the rarity of cardiogenic unilateral edema in the left lung. This clinical finding was associated with the prolonged rest on the left side during the gastrointestinal endoscopic procedure.


Assuntos
Endoscopia Gastrointestinal/efeitos adversos , Edema Pulmonar/etiologia , Idoso , Fibrilação Atrial , Feminino , Humanos , Hipertensão , Fatores de Risco
5.
Rev. am. med. respir ; 13(4): 239-242, dic. 2013. ilus
Artigo em Espanhol | LILACS | ID: lil-708613

RESUMO

La hipertensión arterial pulmonar (HAP) es una enfermedad rara caracterizada por un incremento progresivo de las resistencias vasculares pulmonares que lleva a la falla cardíaca derecha y muerte prematura. La enfermedad puede ser idiopática o asociada a otras condiciones como la hipertensión portal, el virus de la inmunodeficiencia humana, las enfermedades del tejido conectivo, las cardiopatías congénitas con cortocircuitos de izquierda a derecha o asociadas a diferentes toxinas o drogas. Se han realizado avances en el tratamiento farmacológico enfocados en el remodelado de la vasculatura pulmonar. En este sentido, se encuentran en evaluación los inhibidores de la tirosina kinasa (ITK). El imatinib es un ITK selectivo aprobado para el tratamiento de la leucemia mieloide crónica (LMC) que ha demostrado beneficios en el tratamiento de la HAP en estudios de fase II. Paradójicamente, el ITK dasatinib, también aprobado para el tratamiento de la LMC, ha sido asociado a HAP, falla ventricular derecha y a derrame pleural, lo que sugiere la posibilidad de un efecto adverso a nivel pulmonar vinculado con esta droga.


Pulmonary arterial hypertension is a rare disease that is characterized by a progressive increase in vascular pulmonary resistance, chronic right ventricle failure and premature death. Pulmonary arterial hypertension can be either idiopathic or associated to other conditions such as portal hypertension, human immunodeficiency virus, connective tissue diseases, congenital systemic-to-pulmonary shunts or associated to different drugs/toxins. Encouraging progress has been made by targeting the main vasoproliferative aspects of the disease. Tyrosine kinase inhibitors (TKI) are promising emerging therapeutics. Imatinib, a selective TKI approved for the treatment of chronic myeloid leukaemia, has demonstrated some efficacy in treating pulmonary arterial hypertension in a phase II study. However, the TKI dasatinib, also approved for therapy of chronic myeloid leukaemia, has been linked to reversible pulmonary arterial hypertension and right ventricular failure, with pleural effusion, suggesting the possibility of drug-related pulmonary arterial hypertension.


Assuntos
Leucemia , Toxicidade , Hipertensão Arterial Pulmonar
7.
Prensa méd. argent ; 97(2): 75-80, abr. 2010. ilus
Artigo em Espanhol | LILACS | ID: lil-601734

RESUMO

Raynaud's phenomenon is a common disorder with vasospasm of the digital arteries causing pallor with cyanosis and/or rubor. It can be primary (idiopathic), where it is not associated with other diseases, or secondary to several diseases or conditions, including connective tissue diseases, such as scleroderma and systemic lupus erythematosus. Capillaroscopy is the most reliable way to distinguish between primary and secondary Raynaud's phenomenon through identification of an early pattern of systemic sclerosis. Treatment is often non-pharmacological, including avoiding cold and smoking cessation. Calcium channel antagonists are often considered when treatment is needed.


Assuntos
Humanos , Esquema de Medicação , Doença de Raynaud/diagnóstico , Doença de Raynaud/terapia , Escleroderma Sistêmico/diagnóstico , Angioscopia Microscópica , Prostaglandinas/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA